UK Neurology Clinical Trials Market Analysis

UK Neurology Clinical Trials Market Executive Summary

The UK Neurology Clinical Trials market is projected to grow from $342.2 Mn in 2022 to $451.4 Mn by 2030, registering a CAGR of 3.52% during the forecast period of 2022 - 2030. The NHS delivers high-quality treatment by global standards; the United Kingdom's healthcare system was placed 10th overall in the 2021 Global Index of Health Innovation. Healthcare costs around 18% of a citizen's income tax, or 4.5% of an ordinary citizen's income. In the United Kingdom, 600,000 people have epilepsy, accounting for around one in every 100 persons. Every day, 87 individuals are diagnosed. Currently, Parkinson's Disease affects 145,000 persons in the United Kingdom.

Neurology clinical trials are a significant field of study in the United Kingdom, with several studies now underway. Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and stroke are among the conditions being examined. The National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) provides researchers with the practical assistance they need to make clinical trials happen in both the NHS and the broader healthcare and social care setting. The CRN funds research in 30 different speciality therapeutic areas. There are also various neurological research organisations in the UK, such as the UK Dementia Research Institute, Parkinson's UK, and the MS Society. In their particular areas of specialisation, these organisations invest in research as well as provide resources and assistance for clinical trials.

Market Dynamics

Market Growth Drivers

The UK has a solid clinical trial ecosystem, including a well-developed regulatory framework, a matrix of research centres and hospitals, and an engaged patient population. The significant worldwide burden of neurological illnesses has raised financial support and shareholders’ interest in supporting neurological clinical investigations is on the rise. The National Institute for Health Research (NIHR) funds and supports clinical trials in the UK and collaborates closely with the NHS to ensure that studies are carried out to the highest standards. Furthermore, the UK has a varied and active patient population, which makes it a desirable place for clinical studies. The UK is a thriving centre for neurology clinical trials, and it is expected to make substantial contributions to the progress of the management and understanding of neurological disorders.

Market Restraints

According to current data, the UK has lesser neurology consultants than other high-income nations. There have been concerns with regard to the impact on those with neurological problems obtaining timely access to health and care services. There are additionally more factors that may have an influence on the growth of neurology clinical trials in the UK. One such constraint is the increased struggle for financing, as many other areas of study demand funds as well. Also, the regulatory environment for clinical trials can be complicated and time-consuming, which can add to the cost and duration of investigations.

There is also the possibility that Brexit may have an influence on clinical trials in the UK, as the country's withdrawal from the EU will limit its capacity to partner with other nations and access specific funding sources.

Competitive Landscape

Global Key Players

• Pfizer Inc.
• Biogen Inc.
• Novartis AG,
• Roche Holding AG
• Eli Lilly and Company
• Sanofi SA
• AstraZeneca PLC
• Merck & Co. Inc
• Johnson & Johnson Services, Inc.
• GlaxoSmithKline PLC

Local Key Players

• Cambridge Cognition Holdings PLC - Cambridge Cognition is a prominent neuroscience technology firm that uses scientifically established digital health solutions to improve cognitive assessment for improved brain health research
• IXICO PLC - IXICO specialises in the gathering, optimization, and analytics of data for uncommon neurological conditions such as Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA)
• Neuro-Bio Ltd. - Neuro-Bio is a privately held firm based at Oxford University that is focusing on the development of oral medications to treat Alzheimer's disease
• Nodthera Ltd.- NodThera is a biotechnology business that treats chronic illnesses by addressing the cause of inflammation

Notable Insights

February 2023, Pfizer announced that Phase 3 data for Zavegepant for the Acute Management of Migraine in Adults was published in The Lancet Neurology.

November 2022, Biogen Inc. and Eisai Co., Ltd. announced the findings of Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta (A) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed amyloid pathology in the brain.

Healthcare Policies and Regulatory Landscape

The Medicines and Healthcare products Regulatory Agency is the regulatory authority in the UK in charge of clinical trials (MHRA). The MHRA guarantees that clinical trials are done safely and ethically and that the items being tested fulfil the appropriate quality, safety, and efficacy requirements.

Reimbursement Scenario

In the United Kingdom, clinical trials are funded by a variety of public and private organisations, including charities (typically focused on a specific disease), the UK government through organizations such as the National Institute for Health Research (NIHR) or the Medical Research Council (MRC), pharmaceutical companies, and international organisations.